Complement System and the Kidney: Its Role in Renal Diseases, Kidney Transplantation and Renal Cell Carcinoma

Francesco Lasorsa(University of Bari Aldo Moro), Giuseppe Lucarelli(University of Bari Aldo Moro), Michele Battaglia(University of Bari Aldo Moro), Martina Milella(University of Bari Aldo Moro), Pasquale Ditonno(University of Bari Aldo Moro), Felice Crocetto(University of Naples Federico II), Monica Rutigliano(University of Bari Aldo Moro), Savio Domenico Pandolfo(University of L'Aquila), Loreto Gesualdo(University of Bari Aldo Moro), Simona Simone(University of Bari Aldo Moro), Matteo Ferro(European Institute of Oncology)
International Journal of Molecular Sciences
November 20, 2023
10.3390/ijms242216515
Cited by 98

Related Papers

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
|The Lancet|2023|264
Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma
|Aging|2018|247
Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets
|International Journal of Molecular Sciences|2022|190
Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice
|Biomedicines|2023|161
Association of NAFLD and Insulin Resistance with Non Metastatic Bladder Cancer Patients: A Cross-Sectional Retrospective Study
|Journal of Clinical Medicine|2021|131